Understanding how viruses hijack cellular machinery could unlock new therapeutic targets for pandemic preparedness. The endosomal pathway, where many viruses complete their entry into cells, relies on precise lipid chemistry that may represent an exploitable vulnerability. New mechanistic research reveals why blocking PIKfyve, a lipid kinase that generates specific phosphoinositides PI(5)P and PI(3,5)P2, selectively prevents certain enveloped viruses from completing membrane fusion while sparing others like vesicular stomatitis virus. The study demonstrates that PIKfyve inhibition disrupts the endosomal environment necessary for viral membrane fusion, effectively trapping viruses in cellular compartments where they cannot access the cytoplasm to initiate infection. This selectivity appears related to how different viruses navigate the endosomal maturation process and their specific fusion requirements. The finding builds on previous observations that PIKfyve inhibitors like apilimod showed antiviral activity against SARS-CoV-2 and other pathogens, but the underlying mechanism remained unclear. This represents a potentially significant advance in antiviral strategy because targeting host cellular processes, rather than rapidly-mutating viral proteins, could provide broader-spectrum protection against emerging variants and novel pathogens. However, therapeutic applications face substantial hurdles since PIKfyve plays essential roles in normal cellular function, including autophagy and lysosomal biogenesis. The challenge lies in achieving selective antiviral effects without disrupting critical cellular processes. While promising for understanding viral entry mechanisms, translating PIKfyve inhibition into practical therapeutics will require sophisticated delivery methods or combination approaches that minimize cellular toxicity while maintaining antiviral efficacy.